Fisetin in Mild Alzheimer's Disease

Sponsor
Sunnybrook Health Sciences Centre
Study ID
NCT07279714
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
60 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Fisetin — OTHER
    Fisetin 20mg/kg/day

Study Details

This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.

Key Dates

First listed
Dec 12, 2025
Start date
Jan 27, 2026
Status verified
Dec 2025
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
5 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Fisetin

Primary Outcome Measure

Incidence of Treatment-Emergent Adverse Events (Safety and tolerability of fisetin) [ Time Frame: 30 days ]

Central Contacts

Find similar trials

Nationwide
Alzheimer's disease trialsNeurology trialsDementia care trialsBrain disorders trialsGeriatrics trials

Related Studies